作者：
Jaume,Capdevila [1]
;
Lisa,Bodei [2]
;
Philippa,Davies [3]
;
Vera,Gorbounova [4]
;
Robert T,Jensen [5]
;
Ulrich P,Knigge [6]
;
Guenter J,Krejs [7]
;
Eric,Krenning [8]
;
Juan Manuel,O'Connor [9]
;
Marc,Peeters [10]
;
Guido,Rindi [11]
;
Ramon,Salazar [12]
;
Marie-Pierre,Vullierme [13]
;
Marianne E,Pavel [14]
;
ENETS 2016 Munich Advisory Board Participants ;
ENETS 2016 Munich Advisory Board Participants
作者单位：
Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spainjcapdevila@vhio.net.
[1]
Memorial Sloan Kettering Cancer Center, New York, New York, USA.
[2]
Neuroendocrine Tumour Unit, Royal Free Hospital, London, United Kingdom.
[3]
Department of Oncology, Institution of Russian Academy of Medical Sciences, Moscow, Russian Federation.
[4]
National Institutes of Health, Bethesda, Maryland, USA.
[5]
Department of Surgery, University of Copenhagen, Copenhagen, Denmark.
[6]
Medical University of Graz, Graz, Austria.
[7]
Cyclotron Rotterdam BV, Erasmus MC, Rotterdam, The Netherlands.
[8]
Alexander Fleming Institute, Caba, Argentina.
[9]
Department of Oncology, Antwerp University Hospital, Antwerp, Belgium.
[10]
Fondazione Policlinico Universitario A. Gemelli IRCCS Roma-Università Cattolica del Sacro Cuore, Rome, Italy.
[11]
Catalan Institute of Oncology, Oncobell Program, IDIBELL, Cerca, Ciberonc, Barcelona, Spain.
[12]
Radiology Department, Beaujon Hôpital Assistance Publique, Paris, France.
[13]
Friedrich-Alexander Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, Erlangen, Germany.
[14]
DOI
10.1159/000493319
PMID
30153686
发布时间
2019-12-17
换一批
换一批
